HCP supportEnroll patients
Support that’s customized because every patient has distinct needs
As a healthcare professional (HCP), you know better than anyone that each patient has medical, information, and support needs that are unique. That’s why we assign each patient a dedicated support team to help ensure the best possible experience. While the program is optional, we encourage patients to take advantage of this service.
We can help your patients by:
- Providing a caring support team from confirmed diagnosis through postsurgery follow-up
- Ensuring a single point of contact to help navigate insurance coverage and connect your patients with financial assistance resources as needed
- Helping to coordinate visits to the ocular gene therapy treatment center of your chosing
- Answering any nonmedical questions along the way
How to enroll patients
First, determine if LUXTURNA® (voretigene neparvovec-rzyl) is right for your patient. The prescription gene therapy is for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Genetic testing is the only way to confirm this gene mutation. Your patients must also have enough viable retinal cells as determined by the treating physician(s), in order to be eligible for treatment. If your patient has not had a genetic test, learn more here.
1Mutations in both copies of the RPE65 gene
2Fill out enrollment form
Submitting this form allows Spark® Therapeutics to enroll your patient in the program and investigate their insurance coverage.
3Schedule consultation
Your patient’s support team will help connect them with an ocular gene therapy treatment center to schedule their consultation to determine eligibility for treatment.
4Completion of a Statement of Medical Necessity (SMN)
Once a patient has met all eligibility requirements for treatment with LUXTURNA®, an ocular gene therapy treatment center specialist fills out a Statement of Medical Necessity (SMN) form for your patient. An SMN confirms eligibility to receive treatment and Spark Generation Patient Services will then begin an insurance benefits investigation.
5Your patient’s journey
Once an enrollment form or a SMN has been received along with the signed and completed patient consent, your patient services team will communicate the next steps with you and your patient.
Participation in Spark Therapeutics Generation Patient Services® is voluntary. Your patient may choose to participate in all, some, or none of the services offered. Participating or deciding not to participate in these services will have no effect on your patient’s ability to get treatment or the nature of your patient’s treatment or care. Spark Therapeutics Generation Patient Services® does not provide medical advice.
Patient Mentor Program: support from someone who’s been there
If your patient is considering treatment with LUXTURNA, it may be helpful to hear from someone who has been there. Spark Therapeutics Generation Patient Services can connect your patient with a patient (or caregiver of a patient) who was previously treated with LUXTURNA.
Mentors are happy to share their stories, but they cannot give medical advice. If your patients or their caregivers have medical questions about inherited retinal disease or the risks and benefits of LUXTURNA, they should talk to you.
Eligibility requirements
To be connected with a mentor, a patient must be a US resident 18 years of age or older and be a patient, or a parent or legal guardian of a patient, who has been diagnosed with a biallelic RPE65 mutation–associated retinal dystrophy. The patient/guardian must sign the consent form.
To learn more about how to get started with a mentor, download this brochure and call Generation Patient Services toll-free at 1-833-SPARK-PS (1-833-772-7577).
Download brochurePhotographs are not of actual patients or caregivers
